Prevalence of Salmonella in stool during the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018

Irene N Kasumba; Helen Powell; Richard Omore; M Jahangir Hossain; Samba O Sow; John Benjamin Ochieng; Henry Badji; Jennifer R Verani; Marc-Alain Widdowson; Sunil Sen; Shamima Nasrin; Jasnehta Permala-Booth; Jennifer A Jones; Anna Roose; Dilruba Nasrin; Ciara E Sugerman; Jane Juma; Alex Awuor; Joquina Chiquita M Jones; Sanogo Doh; Catherine Okoi; Syed M A Zaman; Martin Antonio; Elizabeth Hunsperger; Clayton Onyango; James Platts-Mills; Jie Liu; Eric Houpt; Kathleen M Neuzil; Karen L Kotloff; Sharon M Tennant

doi:10.1093/cid/ciac985

Prevalence of Salmonella in stool during the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018

Irene N Kasumba, Helen Powell, Richard Omore, M Jahangir Hossain, Samba O Sow, John Benjamin Ochieng, Henry Badji, Jennifer R Verani, Marc-Alain Widdowson, Sunil Sen, Shamima Nasrin, Jasnehta Permala-Booth, Jennifer A Jones, Anna Roose, Dilruba Nasrin, Ciara E Sugerman, Jane Juma, Alex Awuor, Joquina Chiquita M Jones, Sanogo DohCatherine Okoi, Syed M A Zaman, Martin Antonio, Elizabeth Hunsperger, Clayton Onyango, James Platts-Mills, Jie Liu, Eric Houpt, Kathleen M Neuzil, Karen L Kotloff, Sharon M Tennant

Research output: Contribution to journal › A1: Web of Science-article › peer-review

18 Downloads (Pure)

Abstract

BACKGROUND: Non-typhoidal Salmonella (NTS) is a common cause of gastroenteritis in young children, with limited data on NTS serovars and antimicrobial resistance in Africa.

METHODS: We determined the prevalence of Salmonella spp. and frequency of antimicrobial resistance among serovars identified in stools of 0-59 month-old children with moderate-to-severe diarrhea (MSD) and controls enrolled in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in The Gambia, Mali, and Kenya in 2015-2018, and compared with data from the Global Enteric Multicenter Study (GEMS; 2007-2010) and the GEMS-1A study (2011). Salmonella spp. was detected by quantitative real-time PCR (qPCR) and culture-based methods. Identification of serovars was determined by microbiological methods.

RESULTS: By qPCR, the prevalence of Salmonella spp. among MSD cases was 4.0%, 1.6%, and 1.9% and among controls was 4.6%, 2.4%, and 1.6% in The Gambia, Mali, and Kenya, respectively, during VIDA. We observed year-to-year variation in serovar distribution and variation between sites. In Kenya, Salmonella enterica serovar Typhimurium decreased (78.1% to 23.1%; P < .001) among cases and controls from 2007 to 2018, whereas serogroup O:8 increased (8.7% to 38.5%; P = .04). In The Gambia, serogroup O:7 decreased from 2007 to 2018 (36.3% to 0%; P = .001) but S. enterica serovar Enteritidis increased during VIDA (2015 to 2018; 5.9% to 50%; P = .002). Only 4 Salmonella spp. were isolated in Mali during all 3 studies. Multidrug resistance was 33.9% in Kenya and 0.8% in The Gambia across all 3 studies. Ceftriaxone resistance was only observed in Kenya (2.3%); NTS isolates were susceptible to ciprofloxacin at all sites.

CONCLUSIONS: Understanding variability in serovar distribution will be important for the future deployment of vaccines against salmonellosis in Africa.

Original language	English
Journal	Clinical Infectious Diseases
Volume	76
Issue number	Suppl.1
Pages (from-to)	S87-S96
Number of pages	10
ISSN	1058-4838
DOIs	https://doi.org/10.1093/cid/ciac985
Publication status	Published - 2023
Externally published	Yes

Keywords

Child
Humans
Child, Preschool
Infant, Newborn
Infant
Prevalence
Salmonella typhimurium
Salmonella enteritidis
Typhoid Fever
Diarrhea/epidemiology
Serogroup
Mali/epidemiology
Vaccines
Anti-Infective Agents
Anti-Bacterial Agents/pharmacology

Access to Document

10.1093/cid/ciac985Licence: CC BY

2023cidi0S87Final published version, 931 KBLicence: CC BY

Cite this

Kasumba, I. N., Powell, H., Omore, R., Hossain, M. J., Sow, S. O., Ochieng, J. B., Badji, H., Verani, J. R., Widdowson, M.-A., Sen, S., Nasrin, S., Permala-Booth, J., Jones, J. A., Roose, A., Nasrin, D., Sugerman, C. E., Juma, J., Awuor, A., Jones, J. C. M., ... Tennant, S. M. (2023). Prevalence of Salmonella in stool during the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018. Clinical Infectious Diseases, 76(Suppl.1), S87-S96. https://doi.org/10.1093/cid/ciac985

@article{189b75e5c7b54088ad2dfe1b64970bd3,

title = "Prevalence of Salmonella in stool during the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018",

abstract = "BACKGROUND: Non-typhoidal Salmonella (NTS) is a common cause of gastroenteritis in young children, with limited data on NTS serovars and antimicrobial resistance in Africa.METHODS: We determined the prevalence of Salmonella spp. and frequency of antimicrobial resistance among serovars identified in stools of 0-59 month-old children with moderate-to-severe diarrhea (MSD) and controls enrolled in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in The Gambia, Mali, and Kenya in 2015-2018, and compared with data from the Global Enteric Multicenter Study (GEMS; 2007-2010) and the GEMS-1A study (2011). Salmonella spp. was detected by quantitative real-time PCR (qPCR) and culture-based methods. Identification of serovars was determined by microbiological methods.RESULTS: By qPCR, the prevalence of Salmonella spp. among MSD cases was 4.0%, 1.6%, and 1.9% and among controls was 4.6%, 2.4%, and 1.6% in The Gambia, Mali, and Kenya, respectively, during VIDA. We observed year-to-year variation in serovar distribution and variation between sites. In Kenya, Salmonella enterica serovar Typhimurium decreased (78.1% to 23.1%; P < .001) among cases and controls from 2007 to 2018, whereas serogroup O:8 increased (8.7% to 38.5%; P = .04). In The Gambia, serogroup O:7 decreased from 2007 to 2018 (36.3% to 0%; P = .001) but S. enterica serovar Enteritidis increased during VIDA (2015 to 2018; 5.9% to 50%; P = .002). Only 4 Salmonella spp. were isolated in Mali during all 3 studies. Multidrug resistance was 33.9% in Kenya and 0.8% in The Gambia across all 3 studies. Ceftriaxone resistance was only observed in Kenya (2.3%); NTS isolates were susceptible to ciprofloxacin at all sites.CONCLUSIONS: Understanding variability in serovar distribution will be important for the future deployment of vaccines against salmonellosis in Africa.",

keywords = "Child, Humans, Child, Preschool, Infant, Newborn, Infant, Prevalence, Salmonella typhimurium, Salmonella enteritidis, Typhoid Fever, Diarrhea/epidemiology, Serogroup, Mali/epidemiology, Vaccines, Anti-Infective Agents, Anti-Bacterial Agents/pharmacology",

author = "Kasumba, {Irene N} and Helen Powell and Richard Omore and Hossain, {M Jahangir} and Sow, {Samba O} and Ochieng, {John Benjamin} and Henry Badji and Verani, {Jennifer R} and Marc-Alain Widdowson and Sunil Sen and Shamima Nasrin and Jasnehta Permala-Booth and Jones, {Jennifer A} and Anna Roose and Dilruba Nasrin and Sugerman, {Ciara E} and Jane Juma and Alex Awuor and Jones, {Joquina Chiquita M} and Sanogo Doh and Catherine Okoi and Zaman, {Syed M A} and Martin Antonio and Elizabeth Hunsperger and Clayton Onyango and James Platts-Mills and Jie Liu and Eric Houpt and Neuzil, {Kathleen M} and Kotloff, {Karen L} and Tennant, {Sharon M}",

note = "FTX; {\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. (CC BY 4.0)",

year = "2023",

doi = "10.1093/cid/ciac985",

language = "English",

volume = "76",

pages = "S87--S96",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "Suppl.1",

}

Kasumba, IN, Powell, H, Omore, R, Hossain, MJ, Sow, SO, Ochieng, JB, Badji, H, Verani, JR, Widdowson, M-A, Sen, S, Nasrin, S, Permala-Booth, J, Jones, JA, Roose, A, Nasrin, D, Sugerman, CE, Juma, J, Awuor, A, Jones, JCM, Doh, S, Okoi, C, Zaman, SMA, Antonio, M, Hunsperger, E, Onyango, C, Platts-Mills, J, Liu, J, Houpt, E, Neuzil, KM, Kotloff, KL & Tennant, SM 2023, 'Prevalence of Salmonella in stool during the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018', Clinical Infectious Diseases, vol. 76, no. Suppl.1, pp. S87-S96. https://doi.org/10.1093/cid/ciac985

TY - JOUR

T1 - Prevalence of Salmonella in stool during the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018

AU - Kasumba, Irene N

AU - Powell, Helen

AU - Omore, Richard

AU - Hossain, M Jahangir

AU - Sow, Samba O

AU - Ochieng, John Benjamin

AU - Badji, Henry

AU - Verani, Jennifer R

AU - Widdowson, Marc-Alain

AU - Sen, Sunil

AU - Nasrin, Shamima

AU - Permala-Booth, Jasnehta

AU - Jones, Jennifer A

AU - Roose, Anna

AU - Nasrin, Dilruba

AU - Sugerman, Ciara E

AU - Juma, Jane

AU - Awuor, Alex

AU - Jones, Joquina Chiquita M

AU - Doh, Sanogo

AU - Okoi, Catherine

AU - Zaman, Syed M A

AU - Antonio, Martin

AU - Hunsperger, Elizabeth

AU - Onyango, Clayton

AU - Platts-Mills, James

AU - Liu, Jie

AU - Houpt, Eric

AU - Neuzil, Kathleen M

AU - Kotloff, Karen L

AU - Tennant, Sharon M

N1 - FTX; © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. (CC BY 4.0)

PY - 2023

Y1 - 2023

N2 - BACKGROUND: Non-typhoidal Salmonella (NTS) is a common cause of gastroenteritis in young children, with limited data on NTS serovars and antimicrobial resistance in Africa.METHODS: We determined the prevalence of Salmonella spp. and frequency of antimicrobial resistance among serovars identified in stools of 0-59 month-old children with moderate-to-severe diarrhea (MSD) and controls enrolled in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in The Gambia, Mali, and Kenya in 2015-2018, and compared with data from the Global Enteric Multicenter Study (GEMS; 2007-2010) and the GEMS-1A study (2011). Salmonella spp. was detected by quantitative real-time PCR (qPCR) and culture-based methods. Identification of serovars was determined by microbiological methods.RESULTS: By qPCR, the prevalence of Salmonella spp. among MSD cases was 4.0%, 1.6%, and 1.9% and among controls was 4.6%, 2.4%, and 1.6% in The Gambia, Mali, and Kenya, respectively, during VIDA. We observed year-to-year variation in serovar distribution and variation between sites. In Kenya, Salmonella enterica serovar Typhimurium decreased (78.1% to 23.1%; P < .001) among cases and controls from 2007 to 2018, whereas serogroup O:8 increased (8.7% to 38.5%; P = .04). In The Gambia, serogroup O:7 decreased from 2007 to 2018 (36.3% to 0%; P = .001) but S. enterica serovar Enteritidis increased during VIDA (2015 to 2018; 5.9% to 50%; P = .002). Only 4 Salmonella spp. were isolated in Mali during all 3 studies. Multidrug resistance was 33.9% in Kenya and 0.8% in The Gambia across all 3 studies. Ceftriaxone resistance was only observed in Kenya (2.3%); NTS isolates were susceptible to ciprofloxacin at all sites.CONCLUSIONS: Understanding variability in serovar distribution will be important for the future deployment of vaccines against salmonellosis in Africa.

AB - BACKGROUND: Non-typhoidal Salmonella (NTS) is a common cause of gastroenteritis in young children, with limited data on NTS serovars and antimicrobial resistance in Africa.METHODS: We determined the prevalence of Salmonella spp. and frequency of antimicrobial resistance among serovars identified in stools of 0-59 month-old children with moderate-to-severe diarrhea (MSD) and controls enrolled in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in The Gambia, Mali, and Kenya in 2015-2018, and compared with data from the Global Enteric Multicenter Study (GEMS; 2007-2010) and the GEMS-1A study (2011). Salmonella spp. was detected by quantitative real-time PCR (qPCR) and culture-based methods. Identification of serovars was determined by microbiological methods.RESULTS: By qPCR, the prevalence of Salmonella spp. among MSD cases was 4.0%, 1.6%, and 1.9% and among controls was 4.6%, 2.4%, and 1.6% in The Gambia, Mali, and Kenya, respectively, during VIDA. We observed year-to-year variation in serovar distribution and variation between sites. In Kenya, Salmonella enterica serovar Typhimurium decreased (78.1% to 23.1%; P < .001) among cases and controls from 2007 to 2018, whereas serogroup O:8 increased (8.7% to 38.5%; P = .04). In The Gambia, serogroup O:7 decreased from 2007 to 2018 (36.3% to 0%; P = .001) but S. enterica serovar Enteritidis increased during VIDA (2015 to 2018; 5.9% to 50%; P = .002). Only 4 Salmonella spp. were isolated in Mali during all 3 studies. Multidrug resistance was 33.9% in Kenya and 0.8% in The Gambia across all 3 studies. Ceftriaxone resistance was only observed in Kenya (2.3%); NTS isolates were susceptible to ciprofloxacin at all sites.CONCLUSIONS: Understanding variability in serovar distribution will be important for the future deployment of vaccines against salmonellosis in Africa.

KW - Child

KW - Humans

KW - Child, Preschool

KW - Infant, Newborn

KW - Infant

KW - Prevalence

KW - Salmonella typhimurium

KW - Salmonella enteritidis

KW - Typhoid Fever

KW - Diarrhea/epidemiology

KW - Serogroup

KW - Mali/epidemiology

KW - Vaccines

KW - Anti-Infective Agents

KW - Anti-Bacterial Agents/pharmacology

U2 - 10.1093/cid/ciac985

DO - 10.1093/cid/ciac985

M3 - A1: Web of Science-article

C2 - 37074429

SN - 1058-4838

VL - 76

SP - S87-S96

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - Suppl.1

ER -

Prevalence of Salmonella in stool during the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018

Abstract

Keywords

Access to Document

Fingerprint

Cite this